GPC3 and neoplasm: These results proved that similar to the tumor-derived C9HuH-7exo, HN3LC9-293exo also could deliver the plasmid DNA into the recipient cancer cells via their HN3-GPC3 mediated target specificity and thus act as effective natural carriers for CRISPR/Cas9 delivery platform.